GSK eyes first-line use for leukaemia drug Arzerra PMLiVE However, the product has been slow to gain traction in the CLL market, mainly because it has been reserved for use as a second-line therapy and has found it hard to displace Roche's Rituxan/MabThera (rituximab) as the dominant therapy in the anti-CD20 ... |
